Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057512 · ClinicalTrials.gov registry record · Phase 1
Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck
A Phase 1 study of Head and Neck Neoplasms, sponsored by Erimos Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00057512: Completed Phase 1 study of Head and Neck Neoplasms, sponsored by Erimos Pharmaceuticals.
NCT00057512 is a Phase 1 study of Head and Neck Neoplasms that has completed, run by Erimos Pharmaceuticals. The registered enrollment target is 9 participants, below the 265-participant average among 23 other Head and Neck Neoplasms trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057512, a Phase 1 study of Head and Neck Neoplasms, has completed, sponsored by Erimos Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study will be to determine the safety and tolerability of intratumoral M4N. Patients suffering from cancer of the head and neck that is recurrent after primary treatment with surgery, radiation therapy, and/or chemotherapy may be eligible. The design is a Phase 1 dose escalation study of M4N administered intratumorally once weekly, initially for three weeks. Dose will be escalated on the starting schedule to a target of 20 mg/cm3 tumor volume and then, new patient cohorts will have their schedule extended to weekly M4N for 4 weeks. Dose escalation will continue, assuming tolerability, so that cohorts will be treated for 6 weeks, and finally, 8 weeks.
Conditions Studied
Interventions
- DRUG M4N
Study Locations (1)
South Carolina
- MUSC - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-12 |
| Phase | Phase 1 |
What the finished NCT00057512 record still lists
NCT00057512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 265-participant average among 23 other Head and Neck Neoplasms trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Head and Neck Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which M4N is the first listed.
NCT00057512 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT00057512 about?
NCT00057512 is a clinical study titled "Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck". The purpose of this study will be to determine the safety and tolerability of intratumoral M4N. Patients suffering from cancer of the head and neck that is recurrent after primary treatment with surgery, radiation therapy, and/or chemotherapy may be eligible. The design is a Phase 1 dose escalation ...
What is the current status of trial NCT00057512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2003-01. Estimated completion is 2003-12.
What conditions does trial NCT00057512 study?
This clinical trial studies the following conditions: Head and Neck Neoplasms.
What interventions are being tested in trial NCT00057512?
The interventions under investigation include: M4N (DRUG).
Who is sponsoring clinical trial NCT00057512?
This trial is sponsored by Erimos Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00057512 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00057512's enrollment target sits among peer trials
9 24th of 23 the lowest of 23 other Head and Neck Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
-
First in Human Study of AZD9592 in Solid Tumors
RECRUITING · Phase 1
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia